We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| KALA BIO Inc | NASDAQ:KALA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.07 | 6.75 | 7.35 | 0 | 12:00:03 |
From Jul 2022 to Jul 2024
By Sabela Ojea
Shares of Kala Pharmaceuticals Inc. on Tuesday jumped about 79% in after-hours trading after the company said the U.S. Food and Drug Administration accepted its investigational new drug application for the treatment of an eye rare condition through its KPI-012 product candidate.
Shares were trading about 79% higher at $7.01. For the year, shares are down about 94%.
The pharmaceutical company said KPI-012 is aimed at treating persistent corneal epithelial defects, which can result after a corneal injury.
"We are working closely with investigators to initiate our Phase 2b clinical trial of KPI-012 for PCED in the first quarter of 2023," Chief Medical Officer Kim Brazzell said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 27, 2022 16:34 ET (21:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year KALA BIO Chart |
1 Month KALA BIO Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
